SANUWAVE Health, Inc.

SANUWAVE Health, Inc.

SNWVNYSE / NASDAQHealthcareSmall cap

$1.50-$0.09 (-5.7%)

Last close · Data as of Nov 20, 2026

Market cap
$132.3M
P/E
11.2x
EV / EBITDA
7.4x
Revenue
$44.1M
Net margin
26.8%
ROCE
25.4%

This period includes a one-day price step on 5 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

SANUWAVE Health, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
Hidden
3M
Hidden
6M
Hidden
1Y
Hidden
5Y
Short history
  • This period includes a one-day price step on 5 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
  • A period is left blank when the price history is shorter than the period.

52-week range

This period includes a one-day price step on 5 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.09 (-5.7%) from $1.59 to $1.50 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SNWV, bought on each weekday since 2024.

News & filings

What SANUWAVE Health filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was 0.33 times net profit in fiscal 2025.

Strengths (1)

  • Return on capital employed of 25.4%.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
  • This period includes a one-day price step on 5 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.

Read moreShow less

SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.

Sector
Healthcare
Shares outstanding
8.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$132.3M
P/E
11.2x
P/B
81.7x
EV / EBITDA
7.4x
EV / Sales
3.3x
P/S
3.0x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
11.2%
Net margin
26.8%
EBITDA margin
44.1%
ROE
729.6%
ROCE
25.4%
ROIC
142.6%
ROA
31.6%
Asset turnover
1.18

Growth

Revenue
$44.1M
Revenue growth, 1Y
35.0%
Revenue CAGR, 3Y
38.1%
Net profit growth, 1Y
-135.7%
Free cash flow
$1.9M

Solvency

Current ratio
1.38
Debt / Equity
14.19
Debt / Assets
0.62
CFO / Net profit
0.33
Cash / Market cap
9.0%

Where the revenue went

Of every $100 of FY2025 revenue, $27 was left as net income.

SANUWAVE Health, Inc. income statement flow, FY2025
SANUWAVE Health, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$10.1M
RevenueGross profit$34.0M
Gross profitResearch and development$1.4M
Gross profitSelling, general and administrative$26.8M
Gross profitOther operating expenses$890.0k
Gross profitOperating income$4.9M
Operating incomePretax income$4.9M
Interest and other incomePretax income$7.0M
Pretax incomeTax and other$90.0k
Pretax incomeNet income$11.8M

Revenue and net profit

Revenue grew 35.0% in FY2025; net profit is the dashed line.

SANUWAVE Health, Inc. revenue and net profit by fiscal year
SANUWAVE Health, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$16.7M-$10.3M
FY2023$20.4M-$25.8M
FY2024$32.6M-$33.1M
FY2025$44.1M$11.8M

Cash flows

FY2025: $3.9M from operations, $1.9M free after investment (dashed).

SANUWAVE Health, Inc. operating and free cash flow by fiscal year
SANUWAVE Health, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$17.2M-$17.2M
FY2023-$4.5M-$4.5M
FY2024$2.5M$2.0M
FY2025$3.9M$1.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$44.1M+35.0%1Y
EBITDA
$19.4M
Net profit
$11.8M
Cash from operations
$3.9M+57.9%1Y
Free cash flow
$1.9M-1.6%1Y
Revenue CAGR, 3Y
38.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$44.1M$19.4M$11.8M$1.9M729.6%+35.0%-135.7%

Monthly returns

Month-by-month returns of SNWV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$37.3M
Liabilities$35.7M
Equity$1.6M
Paid-in capital$244.3M
Retained earnings-$242.7M

Market cap against peers

8 peers: same sector, nearest by size.

  1. CVRx, Inc.$156.0M
  2. SANUWAVE Health, Inc. (this company)$132.3M

Peers map

Healthcare companies placed by value, growth and quality; SNWV highlighted.

P/E against peers

SNWV trades at 11.2x earnings against a peer median of -2.8x.

  1. SANUWAVE Health, Inc. (this company)11.2x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): TuHURA Biosciences, Inc., Aldeyra Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
SANUWAVE Health, Inc.SNWVthis company$132.3M11.2x81.7x729.6%7.4x
CVRx, Inc.CVRX$156.0M—4.0x-135.6%—
Nano-X Imaging Ltd.NNOX$144.1M-1.9x1.0x-53.7%-2.1x
Health Catalyst, Inc.HCAT$143.4M-0.8x0.6x-72.4%-2.6x
TuHURA Biosciences, Inc.HURA$139.5M-4.6x6.8x-145.5%-4.7x
AVITA Medical, Inc.RCEL$134.2M-2.8x-8.1x291.8%-4.1x
MaxCyte, Inc.MXCT$131.8M-3.0x0.8x-26.0%-3.2x
The Joint Corp.JYNT$117.3M40.3x7.8x19.3%118.2x
Aldeyra Therapeutics, Inc.ALDX$106.2M-3.1x2.4x-76.5%-1.6x
Peer median—-2.8x1.7x-63.0%-2.6x

Year-to-date ROI

SNWV since 1 January, against earlier years.

Historical volatility

SNWV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

SANUWAVE Health, Inc. operating margin by fiscal year
SANUWAVE Health, Inc. operating margin by fiscal year
DateOperating margin
FY2022-53.5%
FY2023-2.6%
FY202411.8%
FY202511.2%
LineFY2025
Cost of revenueCost Of Revenue$10.1M
Gross profitGross Profit$34.0M
Operating expensesOperating Expense$29.0M
Research and developmentResearch And Development$1.4M
Depreciation and amortisationDepreciation And Amortization In Income Statement$880.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$880.0k
Depreciation income statementDepreciation Income Statement$880.0k
Total expensesTotal Expenses$39.1M
Pretax incomePretax Income$11.9M

Learn while you research

Academy chapters picked for SANUWAVE Health, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 11.2 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing35% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Leverage RatiosDebt/Equity of 14.19 is elevated, understand what that means for solvency.6 min read
  5. 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  6. 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
Browse the full Equiscale Academy →